Theravance Biopharma (TBPH) Net Margin (2013 - 2026)
Theravance Biopharma (TBPH) posted quarterly Net Margin of 28.08% for Q1 2026, up 6016.0% year-over-year from 0.46% in Q1 2025, and down 144.98% quarter-over-quarter from 62.43% in Q4 2025.
Powered by 
Analysis
Theravance Biopharma (TBPH) Net Margin (2013 - 2026) Analysis & Trends
Theravance Biopharma (TBPH) has reported Net Margin for 14 consecutive years, with 28.08% the latest figure, recorded in Q1 2026.
- In Q1 2026, Net Margin rose 6016.0% year-over-year to 28.08%; the TTM figure through Mar 2026 stood at 74.81% (up 16419.0% YoY), while the FY2025 annual figure was 934.52%, up 102215.0% from the prior year.
- Net Margin eased to 28.08% in Q1 2026 per TBPH's latest filing, from 62.43% in the prior quarter.
- Across five years, Net Margin topped out at 7445.92% in Q3 2022 and bottomed at 208.2% in Q1 2023.
- Historically, Net Margin has averaged 421.58% across 5 years, with a median of 30.19% in 2023.
- Annual changes were most pronounced in 2022 — Net Margin jumped 728977 bps — and 2023, when it plunged 750295 bps.
- Theravance Biopharma's Net Margin stood at 26.58% in 2022, then tumbled by 214 bps to 30.19% in 2023, then sank by 174 bps to 82.79% in 2024, then surged by 175 bps to 62.43% in 2025, then sank by 145 bps to 28.08% in 2026.
- Business Quant data shows TBPH's Net Margin at 28.08% in Q1 2026, 62.43% in Q4 2025, and 18.08% in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 32.99% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 30.23% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 31.16% |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -539.31% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 13.90% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 12.74% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 12.09% |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -3.12% |
| 10 | Theravance Biopharma | 882.99 Mn | 495.33 Mn | - | -28.45% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -28.45% |
| Mar 31, 2026 | -27.87% |
| Dec 31, 2025 | 107.88% |
| Sep 30, 2025 | 18.08% |
| Jun 30, 2025 | 209.33% |
| Mar 31, 2025 | -88.24% |
| Dec 31, 2024 | -133.91% |
| Sep 30, 2024 | -75.28% |
| Jun 30, 2024 | -115.94% |
| Mar 31, 2024 | -80.42% |
| Dec 31, 2023 | -48.45% |
| Sep 30, 2023 | -57.03% |
| Jun 30, 2023 | -113.79% |
| Mar 31, 2023 | -208.20% |
| Dec 31, 2022 | 1,151.25% |
| Sep 30, 2022 | 7,321.30% |
| Jun 30, 2022 | -39.95% |
| Mar 31, 2022 | -186.93% |
| Dec 31, 2021 | -214.01% |
| Sep 30, 2021 | -267.61% |